Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer.
Thomson DJ, Cruickshank C, Baines H, Banner R, Beasley M, Betts G, Bulbeck H, Charlwood F, Christian J, Clarke M, Donnelly O, Foran B, Gillies C, Griffin C, Homer JJ, Langendijk JA, Lee LW, Lester J, Lowe M, McPartlin A, Miles E, Nutting C, Palaniappan N, Prestwich R, Price JM, Roberts C, Roe J, Shanmugasundaram R, Simões R, Thompson A, West C, Wilson L, Wolstenholme J, Hall E. Thomson DJ, et al. Among authors: palaniappan n. Clin Transl Radiat Oncol. 2022 Nov 21;38:147-154. doi: 10.1016/j.ctro.2022.11.010. eCollection 2023 Jan. Clin Transl Radiat Oncol. 2022. PMID: 36452431 Free PMC article.
Postoperative radiotherapy in human papilloma virus-positive oropharyngeal tumours—a survey of target volume delineation, dose prescription and treatment verification among UK oncologists.
Owadally WS, Evans M, Beasley M, Palaniappan N. Owadally WS, et al. Among authors: palaniappan n. Clin Oncol (R Coll Radiol). 2014 Dec;26(12):804-5. doi: 10.1016/j.clon.2014.09.002. Epub 2014 Oct 3. Clin Oncol (R Coll Radiol). 2014. PMID: 25287295 No abstract available.
PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer.
Owadally W, Hurt C, Timmins H, Parsons E, Townsend S, Patterson J, Hutcheson K, Powell N, Beasley M, Palaniappan N, Robinson M, Jones TM, Evans M. Owadally W, et al. Among authors: palaniappan n. BMC Cancer. 2015 Aug 27;15:602. doi: 10.1186/s12885-015-1598-x. BMC Cancer. 2015. PMID: 26311526 Free PMC article. Clinical Trial.
Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.
Nutting CM, Griffin CL, Sanghera P, Foran B, Beasley M, Bernstein D, Cosgrove V, Fisher S, West CM, Sibtain A, Palaniappan N, Urbano TG, Sen M, Soe W, Rizwanullah M, Wood K, Ramkumar S, Junor E, Cook A, Roques T, Scrase C, Bhide SA, Gujral D, Harrington KJ, Mehanna H, Miah A, Emson M, Gardiner D, Morden JP, Hall E; ART DECO Trial Management Group. Nutting CM, et al. Among authors: palaniappan n. Eur J Cancer. 2021 Aug;153:242-256. doi: 10.1016/j.ejca.2021.05.021. Epub 2021 Jul 10. Eur J Cancer. 2021. PMID: 34256319 Clinical Trial.
Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study.
Vreugdenhil M, Fong C, Iqbal G, Roques T, Evans M, Palaniappan N, Yang H, O'Toole L, Sanghera P, Nutting C, Foran B, Sen M, Al Booz H, Fulton-Lieuw T, Dalby M, Dunn J, Hartley A, Mehanna H. Vreugdenhil M, et al. Among authors: palaniappan n. Clin Oncol (R Coll Radiol). 2021 Dec;33(12):795-803. doi: 10.1016/j.clon.2021.07.009. Epub 2021 Jul 30. Clin Oncol (R Coll Radiol). 2021. PMID: 34340917
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, Boon C, Cook A, De Winton E, Emson M, Foran B, Frogley R, Petkar I, Pettit L, Rooney K, Roques T, Srinivasan D, Tyler J, Hall E; DARS Trialist Group. Nutting C, et al. Lancet Oncol. 2023 Aug;24(8):868-880. doi: 10.1016/S1470-2045(23)00265-6. Epub 2023 Jul 6. Lancet Oncol. 2023. PMID: 37423227 Free article. Clinical Trial.
Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000.
Ness AR, Waylen A, Hurley K, Jeffreys M, Penfold C, Pring M, Leary S, Allmark C, Toms S, Ring S, Peters TJ, Hollingworth W, Worthington H, Nutting C, Fisher S, Rogers SN, Thomas SJ; Head and Neck 5000 Study Team. Ness AR, et al. BMC Cancer. 2014 Dec 17;14:973. doi: 10.1186/1471-2407-14-973. BMC Cancer. 2014. PMID: 25519023 Free PMC article.
18F-FDG-PET in guided dose-painting with intensity modulated radiotherapy in oropharyngeal tumours: A phase I study (FiGaRO).
Michaelidou A, Adjogatse D, Suh Y, Pike L, Thomas C, Woodley O, Rackely T, Palaniappan N, Jayaprakasam V, Sanchez-Nieto B, Evans M, Barrington S, Lei M, Guerrero Urbano T. Michaelidou A, et al. Among authors: palaniappan n. Radiother Oncol. 2021 Feb;155:261-268. doi: 10.1016/j.radonc.2020.10.039. Epub 2020 Nov 5. Radiother Oncol. 2021. PMID: 33161013 Clinical Trial.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Brown JE, Royle KL, Gregory W, Ralph C, Maraveyas A, Din O, Eisen T, Nathan P, Powles T, Griffiths R, Jones R, Vasudev N, Wheater M, Hamid A, Waddell T, McMenemin R, Patel P, Larkin J, Faust G, Martin A, Swain J, Bestall J, McCabe C, Meads D, Goh V, Min Wah T, Brown J, Hewison J, Selby P, Collinson F; STAR Investigators. Brown JE, et al. Lancet Oncol. 2023 Mar;24(3):213-227. doi: 10.1016/S1470-2045(22)00793-8. Epub 2023 Feb 13. Lancet Oncol. 2023. PMID: 36796394 Free article. Clinical Trial.
59 results